Eli Lilly (LLY) Non Operating Income (2009 - 2026)

Eli Lilly has reported Non Operating Income for 18 years, with the latest figure at -$65.0 million in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income rose 72.8% year-over-year to -$65.0 million; the trailing twelve-month figure through Mar 2026 stood at -$397.0 million (up 18.16% YoY), and the FY2025 full-year result was -$571.0 million, down 160.73% from the prior year.
• Non Operating Income for Q1 2026 stood at -$65.0 million, up from -$108.3 million in the prior quarter.
• The five-year high for Non Operating Income was $260.0 million in Q4 2022, with the low at -$350.7 million in Q1 2022.
• Historically, Non Operating Income has averaged -$63.5 million across 5 years, with a median of -$90.6 million in 2025.
• Annual changes were most pronounced in 2022 — Non Operating Income soared 436.35% — and 2025, when it slumped 981.92%.
• Eli Lilly's Non Operating Income stood at $260.0 million in 2022, then sank by 53.35% to $121.3 million in 2023, then plunged by 191.1% to -$110.5 million in 2024, then rose by 1.99% to -$108.3 million in 2025, then soared by 39.98% to -$65.0 million in 2026.
• The last three Non Operating Income figures came in at -$65.0 million (Q1 2026), -$108.3 million (Q4 2025), and -$133.1 million (Q3 2025), per Business Quant data.